The move in FMC (FMC) has been driven less by a single headline and more by a long stretch of weak returns, with the share price down sharply over the past 3 months and year.
At a share price of US$4.68, FMC has seen selling pressure accelerate, with a 7 day share price return down 17.2% and a 90 day share price return down 57%, while the 5 year total shareholder return has fallen 94.7%, signalling fading momentum rather than a short setback.
Shift your attention beyond FMC and scan a curated 35 high quality undervalued stocks that may offer stronger momentum potential than a stock facing this level of pressure.
After a slide this steep, some investors will see FMC at US$4.68 as an opportunity, while others prefer to wait for more clarity. How does the current valuation compare with the value of that patience?
FMC's analyst consensus Narrative on Simply Wall St places fair value at about $7.65 per share, compared with the last close at $4.68. This frames the recent sell off as a discount that assumes the recovery plan is uncertain but not broken.
Strong volume growth is expected from recently launched proprietary actives such as fluindapyr, Isoflex and Dodhylex, together with management’s plan for four new active ingredients to reach US$300 million to US$400 million of revenue in 2026 and around US$800 million by 2027. This could increasingly support FMC revenue and EBITDA as these products scale.
See why 54 investors see FMC as 39% undervalued.
Result: Fair Value of $7.65 (UNDERVALUED)
Still, the FMC thesis carries clear fault lines, including high leverage with interest costs guided around US$275 million to US$285 million, and intense generic competition that could keep pricing under strain.
Find out about the key risks to this FMC narrative.
Mixed sentiment around FMC should prompt you to review the numbers yourself and decide promptly based on your own conclusion, starting with the 3 key rewards and 4 important warning signs.
If FMC no longer feels like the only place your money should work, broaden your watchlist now and give yourself more options before the market moves.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com